Thomas Vedvick, PhD

Director, Process Sciences

 

 

Tom Vedvick joined IDRI in June of 2006. Dr. Vedvick’s research interests are in the development of large scale protein purification and the characterization of proteins for vaccine development. In addition Tom directs the exciting adjuvant formulation program at IDRI.  He has more than 70 original articles, and holds 28 issued U.S. patents for diagnostics, vaccines, and therapeutics of infectious diseases and cancer.

Tom Vedvick was born and raised in the Pacific Northwest. He obtained a BSc in Chemistry from the University of Puget Sound, a MSc in Chemistry from Western Washington State University and his PhD in Biochemistry from Oregon Health Sciences University. Dr. Vedvick’s postgraduate studies were performed at the School of Medicine, University of California, San Diego. During his postgraduate period his scientific interests were focused on hemoglobinopathies. Dr. Vedvick then worked at the Salk Institute Biotechnology Industrial Associates where he led the protein purification and characterization laboratory. While at SIBIA he collaborated on the development of the Pichia pastoris recombinant protein expression system. Tom left SIBIA to work at Telios Pharmaceuticals where he developed peptide based products for wound healing.

Tom then joined Corixa Corporation where he established a protein microsequencing facility and directed the process development group which focused on vaccines for infectious diseases and cancer. Afterwards, Dr. Vedvick spent two years working at LigoCyte pharmaceuticals where he was Director of Process development and project leader in the Norovirus vaccine program. He led the development of purification methods, formulation and cGMP contract manufacturing of the Norovirus,Virus Like Particles. This successful program was the first product that reached a phase I clinical trial for LigoCyte Pharmaceutical.

Recent Publications
1.  Fox CB, Anderson RC, Dutill TS, Goto Y, Reed SG, Vedvick TS. “Monitoring the Effects of Component Structure and Source on Formulation Stability and Adjuvant Activity of Oil-in-Water Emulsions.” 2008 Colloids Surface B Biointerfaces. 65, 98-105.
2.  Vedvick TS, Carter L, Moulton G, Goto Y, Bertholet S, Reed SG, Carter D. “An improved manufacturing process for a polyprotein Vaccine.” 2008 Supplement to Biopharm International 14-22.
3.  Kissmann J, Ausar SF, Foubert TR, Brock J, Switzer MH, Detzi EJ, Vedvick TS, Middaugh CR. “Physical stabilization of norwalk virus-like particles.” 2008 Feb 25 J Pharm Sci.
4.  Ausar SF, Foubert TR, Hudson MH, Vedvick TS, Middaugh CR. “Conformational Stablity and disassembly of Norwalk Virus-like Particles.” 2006 J Biol Chem. 281, 19478-19488.